Disease · MONDO_0009688
Comparisons in its trials46
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 46
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants With Anti-drug Antibodies (ADA) by Week 26 in the Overall Study Population | 1 of 119 | 2 of 119 | 238 | NCT04524273 | Trial comparisons |
| Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants Experiencing Exacerbation by Week 26 in the Overall Study Population | 19 of 119 | 41 of 117 | 236 | NCT04524273 | Trial comparisons |
Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in the Overall Study Population | 79 of 115 | 55 of 114 | 229 | NCT04524273 | Trial comparisons |
| Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in the Overall Study Population | 83 of 95 | 77 of 91 | 186 | NCT04524273 | Trial comparisons |
| Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population | 57 of 95 | 61 of 91 | 186 | NCT04524273 | Trial comparisons |
| Zilucoplan 0.3 mg/kg vs Placebo: deaths from any cause | 1 of 86 | 1 of 88 | 174 | NCT04115293 | Trial comparisons |
| Zilucoplan 0.3 mg/kg vs Placebo: serious adverse events | 11 of 86 | 13 of 88 | 174 | NCT04115293 | Trial comparisons |
| ARGX-113 vs Placebo: deaths from any cause | 0 of 84 | 0 of 83 | 167 | NCT03669588 | Trial comparisons |
| ARGX-113 vs Placebo: serious adverse events | 4 of 84 | 7 of 83 | 167 | NCT03669588 | Trial comparisons |
| Thymectomy Plus Prednisone vs Prednisone Alone: Number of Patients With at Least One Serious Adverse Events | 25 of 66 | 33 of 60 | 126 | NCT00294658 | Trial comparisons |
| Thymectomy Plus Prednisone vs Prednisone Alone: serious adverse events | 25 of 66 | 33 of 60 | 126 | NCT00294658 | Trial comparisons |
| Eculizumab vs Placebo: deaths from any cause | 0 of 62 | 0 of 63 | 125 | NCT01997229 | Trial comparisons |
| Eculizumab vs Placebo: serious adverse events | 9 of 62 | 18 of 63 | 125 | NCT01997229 | Trial comparisons |
| Thymectomy Plus Prednisone vs Prednisone Alone: Azathioprine Use | 11 of 65 | 28 of 58 | 123 | NCT00294658 | Trial comparisons |
| Thymectomy Plus Prednisone vs Prednisone Alone: Intravenous Immunoglobulin Use | 11 of 65 | 23 of 58 | 123 | NCT00294658 | Trial comparisons |
| Thymectomy Plus Prednisone vs Prednisone Alone: Plasma Exchange Use | 10 of 65 | 9 of 58 | 123 | NCT00294658 | Trial comparisons |
| Efgartigimod PH20 SC vs Efgartigimod IV: deaths from any cause | 0 of 55 | 0 of 55 | 110 | NCT04735432 | Trial comparisons |
| Efgartigimod PH20 SC vs Efgartigimod IV: serious adverse events | 8 of 55 | 4 of 55 | 110 | NCT04735432 | Trial comparisons |
| Rozanolixizumab ~7 mg/kg vs Rozanolixizumab ~10 mg/kg: deaths from any cause | 0 of 50 | 0 of 42 | 92 | NCT04124965 | Trial comparisons |
| Rozanolixizumab ~7 mg/kg vs Rozanolixizumab ~10 mg/kg: serious adverse events | 7 of 50 | 2 of 42 | 92 | NCT04124965 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009688/comparisons